SK Life Science has announced the availability of Xcopri (cenobamate) tablets for the treatment of partial-onset seizures in adults. SK Life Science has announced the availability of Xcopri ...
Fycompa bottle Safety data for Fycompa was consistent with the safety profile in adult populations without the need for weight-based dosing. The Food and Drug Administration has expanded the use of ...
Last week, the FDA approved XCOPRI (cenobamate tablets) to treat partial-onset seizures in adults. This approval will help offer additional aid for the many individuals throughout the world who live ...
Post-hoc analysis from open-label Phase 3 study shows treatment with cenobamate led to a reduction of concomitant anti-seizure medications (ASMs) while maintaining ≥50% and 100% seizure reduction ...
Eisai’s Perampanel is Also Forecasted to Earn Peak Year Sales of up to $250 Million, According to Findings from Decision Resources BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the ...
Approval in U.S. follows clearance of potassium-channel opener by European Commission in March. Valeant and its global licensee GlaxoSmithKline (GSK) reported FDA approval of Potiga™ ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced top-line results of a double-blind, placebo-controlled, Phase 3 study evaluating both the 165 mg dose and the 330 mg dose of ...
Since 1983, eight new AEDs have been introduced (see Table 2 below). Sadly, a recent VA study of more than 21,000 subjects aged 65 years and older revealed that 80% were being treated with ...
child yellow pill medicine Safety data for Fycompa was consistent with the safety profile in adult populations without the need for weight-based dosing. The Food and Drug Administration has expanded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results